Orelabrutinib reduces brain lesions in RRMS by 90% in Phase 2 trial
Treatment with InnoCare Pharma’s orelabrutinib ā an experimental inhibitor of the Brutonās tyrosine kinase (BTK) enzyme ā led to significant reductions in new active brain lesions among people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the results of a 12-week interim analysis of a global Phase 2…